CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis

R G Barr¹, J Bourbeau², C A Camargo³, F S F Ram⁴

¹ Irving Assistant Professor of Medicine and Epidemiology, Columbia University Medical Centre, New York, NY, USA
² Associate Professor of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
³ Associate Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
⁴ Senior Lecturer in Respiratory Medicine and Clinical Pharmacology, School of Health Sciences, Massey University, Auckland, New Zealand

Correspondence to:
Dr R G Barr
Division of General Medicine, PH-9 East Room 105, Columbia University Medical Centre, 630 West 168th Street, New York, NY 10032, USA; rgb9{at}columbia.edu

Background: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD).

Methods: A systematic search was made of the Cochrane trials database, MEDLINE, EMBASE, CINAHL, and a hand search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer. Randomised controlled trials of 12 weeks’ duration comparing tiotropium with placebo, ipratropium bromide, or long acting ß₂ agonists (LABA) were reviewed. Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI).

Results: Nine trials (8002 patients) met the inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI 0.19 to 1.29) or all-cause (OR 0.96; 95% CI 0.63 to 1.47) mortality compared with placebo and ipratropium. Reductions in exacerbations and hospitalisations compared with LABA were not statistically significant. Similar patterns were evident for quality of life and symptom scales. Tiotropium yielded greater increases in forced expiratory volume in 1 second (FEV₁) and forced vital capacity (FVC) from baseline to 6–12 months than did placebo, ipratropium, and LABA. Decline in FEV₁ over 1 year was 30 ml (95% CI 7 to 53) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium.

Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations, improved quality of life and symptoms, and may have slowed the decline in FEV₁. Long term trials are warranted to evaluate the effects of tiotropium on decline in FEV₁ and to clarify its role compared with LABA.

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; LABA, long acting ß₂ agonist; SGRQ, St George’s Respiratory Questionnaire; TDI, Transitional Dyspnoea Index

Keywords: tiotropium; chronic obstructive pulmonary disease; emphysema; chronic bronchitis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lee, T. A., Wilke, C., Joo, M., Stroupe, K. T., Krishnan, J. A., Schumock, G. T., Pickard, A. S. (2009). Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 169: 1403-1410 [Abstract] [Full Text]  
• Anzueto, A., Miravitlles, M. (2009). Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther Adv Respir Dis 3: 103-111 [Abstract]  
• Black, P N, McDonald, C F (2009). Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease. Postgrad. Med. J. 85: 141-147 [Abstract] [Full Text]  
• Chen, A. M, Bollmeier, S. G, Finnegan, P. M (2008). Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. The Annals of Pharmacotherapy 42: 1832-1842 [Abstract] [Full Text]  
• Gross, N. J. (2008). Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. Mayo Clin Proc. 83: 1241-1250 [Abstract] [Full Text]  
• Singh, S., Loke, Y. K., Furberg, C. D. (2008). Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA 300: 1439-1450 [Abstract] [Full Text]  
• Oba, Y. (2008). Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?. ANN INTERN MED 148: 626-626 [Full Text]  
• Lin, K., Watkins, B., Johnson, T., Rodriguez, J. A., Barton, M. B. (2008). Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 535-543 [Abstract] [Full Text]  
• Sridhar, M, Taylor, R, Dawson, S, Roberts, N J, Partridge, M R (2008). A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax 63: 194-200 [Abstract] [Full Text]  
• Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., for the INSPIRE Investigators, (2008). The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am. J. Respir. Crit. Care Med. 177: 19-26 [Abstract] [Full Text]  
• Wilt, T. J., Niewoehner, D., MacDonald, R., Kane, R. L. (2007). Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline. ANN INTERN MED 147: 639-653 [Abstract] [Full Text]  
• Bourbeau, J., Ford, G., Zackon, H., Pinsky, N., Lee, J., Ruberto, G. (2007). Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 30: 907-913 [Abstract] [Full Text]  
• Hanania, N. A., Donohue, J. F. (2007). Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. Proc Am Thorac Soc 4: 526-534 [Abstract] [Full Text]  
• Soriano, J. B., Barnes, N. C. (2007). Eppur si muove, or COPD treatment success and inflammation. Eur Respir J 30: 409-410 [Full Text]  
• Chang, J., Mosenifar, Z. (2007). Differentiating COPD From Asthma in Clinical Practice. J Intensive Care Med 22: 300-309 [Abstract]  
• Beeh, K. M., Derom, E., Kanniess, F., Cameron, R., Higgins, M., van As, A. (2007). Indacaterol, a novel inhaled {beta}2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 29: 871-878 [Abstract] [Full Text]  
• Shafazand, S. (2007). Review: long acting {beta}2 adrenoceptor agonists are effective in poorly reversible chronic obstructive pulmonary disease. Evid. Based Med. 12: 12-12 [Full Text]  
• Shafazand, S. (2007). Review: anticholinergics but not {beta}2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD. Evid. Based Med. 12: 13-13 [Full Text]